

# Regulation of cardiac O-GlcNAcylation: More than just nutrient availability

Helen E. Collins<sup>b</sup>, John C. Chatham<sup>a,\*</sup>

<sup>a</sup> Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States of America

<sup>b</sup> Division of Environmental Medicine, Department of Medicine, University of Louisville, Louisville, KY, United States of America



## ARTICLE INFO

### Keywords:

O-GlcNAc  
O-GlcNAc transferase (OGT)  
O-GlcNAcase (OGA)  
Heart  
Nutrient regulation  
Metabolism  
Cardiomyocyte  
GFAT

## ABSTRACT

The post-translational modification of serine and threonine residues of nuclear, cytosolic, and mitochondrial proteins by O-linked  $\beta$ -N-acetyl glucosamine (O-GlcNAc) has long been seen as an important regulatory mechanism in the cardiovascular system. O-GlcNAcylation of cardiac proteins has been shown to contribute to the regulation of transcription, metabolism, mitochondrial function, protein quality control and turnover, autophagy, and calcium handling. In the heart, acute increases in O-GlcNAc have been associated with cardioprotection, such as those observed during ischemia/reperfusion. Conversely, chronic increases in O-GlcNAc, often associated with diabetes and nutrient excess, have been shown to contribute to cardiac dysfunction. Traditionally, many studies have linked changes in O-GlcNAc with nutrient availability and as such O-GlcNAcylation is often seen as a nutrient driven process. However, emerging evidence suggests that O-GlcNAcylation may also be regulated by non-nutrient dependent mechanisms, such as transcriptional and post-translational regulation. Therefore, the goals of this review are to provide an overview of the impact of O-GlcNAcylation in the cardiovascular system, how this is regulated and to discuss the emergence of regulatory mechanisms other than nutrient availability.

## 1. Introduction

The post-translational modification (PTM) of serine and threonine residues of nuclear, cytosolic, and mitochondrial proteins by O-linked  $\beta$ -N-acetyl glucosamine (O-GlcNAc) is a highly dynamic and reversible, nutrient-driven process, and is an important regulator of cell function [1,2]. Protein O-GlcNAcylation contributes to the regulation of the cell cycle, transcription and translation, metabolism, mitochondrial function, protein synthesis, protein quality control and turnover, autophagy, epigenetic signaling, and  $\text{Ca}^{2+}$  handling [3,4].

A major emphasis on the regulation of O-GlcNAc levels has been as a nutrient-driven process, and especially dependent on changes in the availability of glucose. A small portion of glucose that enters the cell is metabolized by the hexosamine biosynthesis pathway (HBP) to uridine diphosphate-GlcNAc (UDP-GlcNAc), the end product of the HBP, and the substrate for protein O-GlcNAcylation and other forms of protein glycosylation. Glucose flux through the HBP is regulated at least in part, by the activity of L-Glutamine: D-fructose-6-phosphate aminotransferase (GFAT), which catalyzes the generation of glucosamine 6-phosphate from fructose 6-phosphate using glutamine as the amine donor. UDP-GlcNAc integrates multiple metabolic pathways providing feedback on overall cellular energy levels and the metabolism of fatty acids, glucose,

nitrogen, and nucleotides [5,6]. In addition to flux through the HBP, O-GlcNAc levels are regulated by O-GlcNAc transferase (OGT), which uses UDP-GlcNAc as its substrate to add the sugar moiety to proteins, and O-GlcNAcase (OGA), which is responsible for its removal. Furthermore, OGT activity is very sensitive to changes in UDP-GlcNAc; consequently, O-GlcNAc levels can also be affected by changes in the availability of UDP-GlcNAc.

It is a common assumption that 2–3% of glucose is metabolized via the HBP; however, this originates from a single study on adipocytes, where the amount of glucose entering the HBP was not directly measured but was estimated based on other measurements [7]. Importantly, this value is presented as a percentage; consequently, given that the rate of glucose utilization varies widely, between for example, cells in culture and the beating heart, it is misleading as to the actual rate of glucose utilization via the HBP. Using  $^{13}\text{C}$ -labeled glucose in neonatal cardiomyocytes it was concluded that glucose metabolism via the HBP could be much higher than previously thought [8]. However, this was an inference from other measurements and not a direct measure of glucose flux via the HBP. In contrast, Olson and colleagues using  $^{13}\text{C}$ -labeled glucose in an isolated perfused heart combined with liquid chromatography-mass spectrometry, measured an HBP flux of  $\sim 2.5$  nmol/g heart protein/min [9]. Of note, the HBP flux measured in this

\* Corresponding author at: Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Biomedical Research Building II, 901 19th St. S, Birmingham, AL 35294-0019, United States America.

E-mail address: [jchatham@uabmc.edu](mailto:jchatham@uabmc.edu) (J.C. Chatham).

<https://doi.org/10.1016/j.bbadis.2020.165712>

Received 1 May 2019; Received in revised form 15 January 2020; Accepted 27 January 2020

Available online 31 January 2020

0925-4439/ © 2020 Elsevier B.V. All rights reserved.

study was not affected by changes in glucose availability and represented only 0.003–0.006% of glycolytic flux [9]. This is the first report of absolute glucose flux through the HBP in the heart and future studies using this technique will provide valuable insights into the regulation of HBP metabolism under physiological or pathophysiological conditions.

The first report indicating that cardiac proteins could be O-GlcNAcylated was the observation that  $\alpha$ ,B crystallin was a target for O-GlcNAc-modification in the rat heart [10]. It was later shown that OGT activity was higher in the rat heart compared to other tissues examined and the authors suggested that increased O-GlcNAcylation of proteins could be a mechanism mediating glucose toxicity [11]. In endothelial cells the transcription factor, specificity factor 1 (Sp1), was also shown to be a target for O-GlcNAc modification, which was increased in response to hyperglycemia and was linked to higher mitochondrial superoxide [12]. It was concluded that this could be linked to glucose toxicity and diabetic complications. A subsequent study by the same group linked O-GlcNAcylation of endothelial nitric oxide synthase (eNOS) to impaired vascular function in diabetes [13]. While many studies have linked chronic increases in O-GlcNAc associated with diabetes and nutrient excess to the adverse cardiac dysfunction of diabetes [14–21], there are also reports demonstrating that acute pharmacological increases in O-GlcNAc are cardioprotective, in ischemia/reperfusion (I/R) [22] and septic shock [23]. In other cases, O-GlcNAc levels are decreased in the heart following I/R [24] and during trauma-hemorrhage [25], with increased tissue injury associated with lower O-GlcNAc levels. Interestingly, both acute and chronic exercise have been shown to reduce O-GlcNAc levels in the heart [26]. Clearly, understanding the regulation of O-GlcNAc levels in the heart under normal and pathological conditions is essential to better understand the consequences of these changes on the heart. The alterations in cardiac O-GlcNAc levels in response to different stimuli are summarized in Fig. 1.

An emerging consensus, as described by Yang and Qian [27], is that there is a limited range of O-GlcNAc levels needed to ensure normal cellular homeostasis and that O-GlcNAcylation is maintained in this range by a balance between OGT/OGA activity and nutrient availability. Consequently, when this homeostatic mechanism fails such that there is too little or too much O-GlcNAc modification there is cellular dysfunction and pathophysiology [27]. It is of note however, that this concept, typically emphasizes increasing nutrients and stress resulting in higher O-GlcNAc levels, however, as noted above, some stresses result in lower O-GlcNAc levels. In addition, this model does not account for the paradoxical increase in O-GlcNAc levels that occurs in response

to glucose deprivation, as we and others have reported [28,29].

In addition to diabetes, increases in cardiac O-GlcNAc levels have been associated with pressure-overload induced hypertrophy [20,30–34], heart failure [31], ischemia [3,24,35], aging [16,36–38], as well as in response to agonists such as phenylephrine (PE) [30,39] and endothelin-1 (ET-1) [40,41]. Such changes in O-GlcNAc levels do not fit neatly with the concept that nutrient availability is the primary regulator of O-GlcNAc levels. Consequently, it is important to better understand the mechanisms that regulate O-GlcNAcylation in the heart. There have been many recent detailed reviews on O-GlcNAcylation in various contexts including the heart [3,4,32,37,42,43]; therefore, here we focus on our understanding of how O-GlcNAc levels are regulated in the heart. In addition to traditional nutrient-driven mechanisms, we will also consider other emerging mechanisms regulating O-GlcNAcylation and their importance in understanding the role of O-GlcNAc in cardiomyocyte function.

### 1.1. Substrate availability and metabolism

In the 1980s it was shown that high glucose in the presence of insulin for 24 h, induced insulin resistance in cultured adipocytes, and further that this was dependent on the presence of glutamine [7]. Overexpression of GFAT also induced insulin resistance [44] and subsequent studies showed that increasing O-GlcNAc by inhibiting OGA blunted insulin-stimulated glucose uptake [45]; however, some reports indicated that increasing O-GlcNAc levels alone was not sufficient to induce insulin resistance [46,47]. Nevertheless, additional studies found that several components of the insulin signaling pathway including Insulin receptor 1/2 (IRS1/2), Phosphoinositide dependent protein kinase 1 (PDK1), Protein kinase B (PKB/Akt), and Glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) were all O-GlcNAcylated and that in each case, increased O-GlcNAc levels attenuated their activity [48–50]. In addition, protein tyrosine phosphatase 1B (PTP1B), which dephosphorylates the insulin receptor is also O-GlcNAcylated, increasing its activity, providing another possible link between O-GlcNAc levels and impaired insulin signaling [51]. These observations along with the concept that glucose toxicity was mediated, at least in part, by increased O-GlcNAcylation of specific proteins, resulted in an early focus on the contribution of increased O-GlcNAc levels to diabetic complications seen in the heart. The role of O-GlcNAc in regulating insulin signaling in the heart has not been studied in detail; however, in diabetes increased O-GlcNAc levels on proteins involved in Ca<sup>2+</sup> handling (i.e., Sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA), Phospholamban (PLB), Ca<sup>2+</sup>/calmodulin dependent kinase II (CaMKII) [17,52,53]), contractile proteins (i.e.,  $\alpha$ -actin, troponin I) [54,55], and mitochondrial proteins (i.e., VDAC1/2, NDUFA9, ATP synthase A/B) [56–58] have all been linked to the adverse effects of diabetes on cardiac function. The sustained increase in O-GlcNAc in the heart in response to diabetes is typically attributed to increased nutrient availability; however, it raises the question as to why the normal homeostatic mechanisms are unable to compensate. It is possible, therefore, that regulation at the level of OGT and OGA function is likely impaired, resulting in a new higher steady state level of O-GlcNAcylation. Similar mechanisms could also contribute to the chronic increase in cardiac O-GlcNAc levels seen in response to hypertrophy and aging, which are not conditions of nutrient excess.

Protein O-GlcNAcylation has also been implicated in regulating cardiac metabolism. Low concentrations of glucosamine were found to increase fatty acid oxidation in the perfused heart, possibly as a result of increased plasma membrane levels of the fatty acid transporter, CD36 [59]. In the heart, glutamine is often considered to be an anaplerotic substrate, feeding directly into the TCA cycle via its metabolism to glutamate and  $\alpha$ -ketoglutarate. However, a study in hearts perfused with <sup>13</sup>C-labeled glutamine found very low levels of <sup>13</sup>C-enrichment in TCA cycle intermediates, suggesting that this was not the primary pathway for glutamine metabolism in the normoxic heart; on the other




Fig. 1. Illustration of the wide range of factors that result in increases or decreases in O-GlcNAc levels in cardiomyocytes or the heart, which are discussed in more detail in the text.

hand, they found that similar to glucosamine, glutamine increased fatty acid oxidation [60]. Additional studies lead to the conclusion that glutamine was being metabolized by the HBP and increasing fatty acid oxidation in a CD36-dependent manner [60]. These studies were consistent with earlier reports in adipocytes demonstrating increased HBP flux, O-GlcNAcylation, and increased fatty acid oxidation [61]. Additional evidence of a link between O-GlcNAcylation and lipid metabolism was the observation that a splice variant of OGA was associated with lipid droplets [62].

A growing number of proteins that regulate glucose metabolism have been identified as targets for O-GlcNAcylation, including Glucose transporter 4 (GLUT4), hexokinase, glycogen synthase, phosphofructokinase, and pyruvate kinase [63]. Studies on the role of O-GlcNAc regulation of glucose metabolism is most advanced in the setting of cancer; however, it is reasonable to expect that similar types of regulation also occur in the heart, particularly in light of the parallels in metabolic remodeling between cancer and the stressed heart [64,65]. In addition, proteins that play key roles in regulating metabolism such as AMP-activated protein kinase (AMPK), Akt, GSK3 $\beta$ , are also modified and regulated by O-GlcNAcylation [48,61]. There is also extensive evidence that O-GlcNAcylation plays an important role in mediating the transcriptional regulation of metabolism via modification of transcription factors such as Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 $\alpha$ ), forkhead transcription factor (FoxO), and cAMP-response element binding protein (CREB) [66–69]. Interestingly, AMPK is O-GlcNAcylated by OGT increasing its activity [70], and GFAT1 is known to be phosphorylated by AMPK [71,72]. In cardiomyocytes, AMPK has been reported to decrease GFAT1 activity [39], suggesting a possible feedback mechanism between the regulation of O-GlcNAc levels via metabolism and O-GlcNAc regulation of metabolism.

### 1.2. Transcriptional regulation

In 2004, it was demonstrated that O-GlcNAc levels in cells increased in response to a number of stressors, including heat shock, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and osmotic shock [73]. It was also shown that this was an endogenous stress response that increased cell survival. The beneficial effects of pharmacologically increasing O-GlcNAc in heart were shown in a number of in vivo and in vitro studies [24,74]. In recent years, some of the mechanisms underlying the changes in O-GlcNAcylation during I/R have been studied. Myocardial I/R in vivo in the mouse, resulted in a marked increase in O-GlcNAc in the ischemic but not the border zone [75]. This was paralleled by significant increases in GFAT1 mRNA and protein, as well as increases in several other enzymes in the HBP that contribute to the regulation of UDP-GlcNAc levels. These findings are consistent with a transcriptional upregulation of the HBP as a contributing factor in the increase in O-GlcNAc levels in the ischemic region. The study found that spliced X-box protein 1 (Xbp1s) levels, a transcription factor regulating unfolded protein response (UPR) gene expression, was markedly upregulated in the ischemic zone, and this was responsible for the upregulation of several proteins in the HBP, including GFAT [75]. Moreover, they also demonstrated that both Xbp1s and GFAT1 were required for the I/R-induced increase in O-GlcNAc and that the Xbp1s-UPR-HBP/GFAT signaling axis was essential for protection in I/R injury [75]. Of note, OGT and OGA were not regulated by Xbp1s, which supports the concept that it was increased availability of UDP-GlcNAc that was the driver of the increase in O-GlcNAc in this instance. However, as the effects of I/R on OGT or OGA activities were not determined, they could also be contributing factors. GFAT has also been shown to be regulated by activating transcription factor 4 (ATF4) [76], another component of the UPR; however, whether this occurs in the heart is not known.

Changes in GFAT, OGT, and OGA protein and mRNA levels in the heart also occur in chronic settings including diabetes, cardiac hypertrophy, and aging. In hearts from diabetic mice OGT mRNA and protein were both significantly increased [53]. In humans and mice with

cardiac hypertrophy, OGT mRNA and protein were also increased in addition to increases in GFAT and OGA [31]. Furthermore, aging increases cardiac O-GlcNAc levels and in the heart this increase in O-GlcNAc was associated with a paradoxical decrease in OGT levels but also with increased UDP-GlcNAc levels and increased GFAT mRNA [36]. While OGA protein levels were not determined, OGA mRNA was significantly increased in response to aging, whereas OGT mRNA was unchanged. Consequently, whether in response to acute stress such as I/R or under more sustained cardiac stresses, GFAT, OGT and OGA are all subject to alterations at both the mRNA and protein levels.

Little is known about the transcriptional regulation of either OGT or OGA in the heart; however, it is clear that changes in protein levels do occur. For example, cardiac O-GlcNAc levels have been shown to exhibit time-of-day dependent changes that occur in parallel with changes in OGT mRNA and protein [77]. While these changes are dependent on the cardiomyocyte circadian clock, the specific mechanisms that regulate cardiac OGT levels are not known. Interestingly, a recent study in liver, showed that REV-ErbA, a core component of the circadian clock, binds to and stabilizes OGT protein levels [78]. Since protein levels of REV-ErbA exhibit time-of-day dependent changes, this could contribute to rhythmic changes in OGT and O-GlcNAc observed in the heart. There is also evidence to suggest that O-GlcNAc levels contribute to the regulation of OGT and OGA expression. For example, low O-GlcNAc levels are associated with increased OGT transcription, whereas pharmacologically increasing O-GlcNAc levels increased OGA protein levels [79,80]. Other studies, using luciferase reporter assays have shown that knockdown of OGA decreased the level of OGT protein, whereas increased OGA expression led to increased OGT transcription [81]. The transcription factor E2F Transcription Factor 1 (E2f1) has been reported to repress both OGT and OGA [82] and E2f1 is O-GlcNAcylated, which in turn could regulate its transcriptional activity [83]. Although this relationship is likely to be more complicated given that Dassanayaka et al. have recently shown that deletion of E2f1 did not impact either OGT or OGA [84]. A recent study has demonstrated that hepatocyte nuclear factor 1 (HNF1) represses OGT transcription, which is enhanced by O-GlcNAcylation of HNF1, indicative of a feedback inhibition mechanism, which provides some insight into potential mechanisms regulating O-GlcNAc homeostasis [85]. In a mouse model of heart failure, increased O-GlcNAcylation is associated with lower OGA protein levels and an upregulation of miRNA-539 [86]. In neonatal cardiomyocytes, miRNA-539 was found to decrease OGA protein levels and this was associated with an increase in O-GlcNAcylation [86]. OGT protein levels also decreased in response to miR-539 overexpression even though it does not contain miR-539 binding sites [86]; this would be consistent with the concept of reciprocal regulation of OGT and OGA. It remains to be determined whether miR-539 represents a physiological mechanism for regulating OGA and O-GlcNAc levels or whether it is primarily a pathogenic mechanism.

### 1.3. Post-translational modification

The three enzymes that play a major role in regulating O-GlcNAc levels, GFAT, OGT, and OGA are all themselves subject to several different post-translational modifications, including phosphorylation, acetylation, and O-GlcNAcylation. GFAT1, the predominant isoform in the heart can be phosphorylated by protein kinase A (PKA), AMPK, and Ca<sup>2+</sup>/calmodulin-dependent protein kinase (CaMK) II. PKA phosphorylates Ser205 and Ser235 on GFAT1 leading to a reduction in its activity [87–89]; however, to our knowledge the role of PKA phosphorylation on HBP flux or O-GlcNAc levels in the heart has yet to be evaluated. GFAT1 is also phosphorylated at Ser243, by AMPK, CaMKII, and mechanistic target of Rapamycin (mTOR) [90]. Since its original description as a target for phosphorylation and activation by CaMKII, little additional information has emerged on the role of CaMKII on regulating GFAT activity [72]. However, there have been more extensive studies on the role of AMPK in regulating GFAT1 activity. Initial reports

indicated that AMPK phosphorylation increased GFAT1 activity [71,72]; however, recent studies in the heart, reported that AMPK activation decreases O-GlcNAc levels via its inhibition of GFAT1 [39]. In response to nutrient limitations, mTOR was found to increase GFAT1 activity by phosphorylating Ser243, but whether this occurs in the heart is unclear. AMPK also phosphorylates OGT (hOGT Thr454; rOGT Thr444), however, rather than altering its activity AMPK-mediated phosphorylation increased OGT translocation to the nucleus, resulting in higher nuclear O-GlcNAcylation and histone acetylation [39].

OGT is extensively phosphorylated (<http://www.phosphosite.org>) [91], however the kinases involved have only been characterized for a limited number of phosphorylation sites. GSK3 $\beta$  phosphorylates OGT (Ser3 or 4), resulting in an increase in activity [92] and insulin-mediated activation of IRS1 leads to tyrosine phosphorylation of OGT (Y976) resulting in both increased activity and O-GlcNAcylation of key components of the insulin signaling pathway [93], such as Akt and GSK3 $\beta$ . In the liver, IP<sub>3</sub>-mediated activation of CaMKII resulted in OGT phosphorylation (Ser20), increasing its activity and contributed to the regulation of liver autophagy [94]. As discussed below, in the heart CaMKII activity has been shown to be regulated by O-GlcNAcylation, however, its role in regulating cardiac O-GlcNAcylation is not known. Checkpoint kinase 1 (Chk1) stabilizes OGT in cell culture by phosphorylating Ser20 [95], which could be of relevance in the heart given the potential role of Chk1 in contributing to the regulation of apoptosis in cardiomyocytes [96]. OGT also O-GlcNAcyates itself [92], including the same sites phosphorylated by GSK3 $\beta$  as well as additional sites in the TPR domain and C-terminus, but the effects of these modifications on OGT function/activity remain unclear. OGT is also acetylated [91], but what impact this has on its function are not known. OGA also has multiple phosphorylation sites; however, the specific regulatory kinases have not been identified. OGA also has an O-GlcNAc modification site (Ser405), which is in the region that is believed to interact with OGT; however, how changes in O-GlcNAcylation of this site affects this interaction remain unknown. It is clear that O-GlcNAc levels can be directly regulated via PTM-mediated changes in activity of the proteins responsible for its regulation. Several of the kinases identified to date, namely AMPK, CaMKII, and GSK3 $\beta$  have well characterized roles in the heart; however, our understanding of their impact on regulating protein O-GlcNAcylation in the heart, remains poorly understood.

#### 1.4. Cross talk between Ca<sup>2+</sup> and O-GlcNAc signaling

As discussed above, Ca<sup>2+</sup>/calmodulin-dependent protein kinase (CaMK) II and IV phosphorylate GFAT1 and OGT, in the case of OGT this is reported to increase its activity [97]. Consequently, it is perhaps surprising that Ca<sup>2+</sup>-dependent regulation of cellular O-GlcNAc levels remains under explored. In 2004, Kneass and Marchase demonstrated that treatment of neutrophils with fMLP (N-formyl-Met-Leu-Phe) resulted in approximately a 5-fold increase in O-GlcNAc levels within 30 s, gradually returning to basal levels over the next few minutes [98]. While this study did not assess Ca<sup>2+</sup> levels, fMLP is recognized as mobilizing intracellular Ca<sup>2+</sup> stores thereby activating calmodulin and calcineurin, and the observed temporal changes in O-GlcNAc levels were consistent with Ca<sup>2+</sup>-dependent activation. Song et al., subsequently reported that depolarization of neuroblastoma cells rapidly increased OGT activity reaching a peak within 1 min resulting in increased O-GlcNAc levels [97]. They also demonstrated that extracellular Ca<sup>2+</sup> was required for the increase in O-GlcNAc and that the increase in O-GlcNAc levels was blocked by CaMKIV inhibition [97]. Studies in other cell types including neonatal cardiomyocytes demonstrated that stress-induced increases in O-GlcNAc levels were also dependent on extracellular Ca<sup>2+</sup> and could be attenuated by inhibition of CaMKII [29]. Leptin [99] and ET-1 [40,41] have both been reported to increase cellular O-GlcNAc levels, and both have been shown to result in activation of CaMKII.

In the heart and isolated cardiomyocytes, PE, which activates the

canonical hypertrophic signaling pathway, increases GFAT1 phosphorylation and O-GlcNAcylation [30,39]. The increase in O-GlcNAc occurred as early as 2-h following treatment and was associated with increases in GFAT protein and cell size over a similar period of time [39]. PE also leads to the activation of the Ca<sup>2+</sup>-dependent phosphatase calcineurin, resulting in the nuclear translocation of nuclear factor of activated T-cells (NFAT). Hyperglycemia has been shown to inhibit this response in an O-GlcNAc-dependent manner and in neonatal cardiomyocytes increased O-GlcNAc levels attenuated angiotensin II-induced increase in cytosolic Ca<sup>2+</sup> [100,101]. On the other hand, Facundo et al., found that increasing O-GlcNAc levels through overexpression of OGT was sufficient to initiate hypertrophic signaling in cardiomyocytes [30], possibly via Ca<sup>2+</sup>/calcineurin mediated pathway. Also, of note, AMPK, which as discussed above regulates both GFAT1 and OGT, can also be activated in a CaMKII-dependent manner. Overall there is strong evidence that OGT activity and O-GlcNAc levels can be increased via activation of canonical Ca<sup>2+</sup> signaling pathways.

The relationship between O-GlcNAcylation and Ca<sup>2+</sup> signaling is complicated by the fact that Ca<sup>2+</sup>-activated proteins such as CaMK are themselves regulated by O-GlcNAc levels. For example, CaMKIV has been shown to have at least 5 individual O-GlcNAc modification sites and that during activation the interaction with OGA increased and O-GlcNAc levels quickly decreased [102]. Conversely, during inactivation O-GlcNAcylation of CaMKIV returned to normal, suggesting increased interaction with OGT [102]. Mutation of one of the O-GlcNAc sites, S189 to alanine to prevent O-GlcNAcylation, markedly reduced overall CaMKIV O-GlcNAcylation and increased basal kinase activity. In the heart, CaMKII has been shown to be O-GlcNAcyated at T286 and S279 and hyperglycemia increased CaMKII activity via increased O-GlcNAcylation of S279 [17]. The hyperglycemia-mediated increase in O-GlcNAc levels was linked to an increased susceptibility to arrhythmias in diabetes. While excessive O-GlcNAc levels result in dysregulation of CaMKII, it does not preclude the possibility of O-GlcNAcylation playing a role in the normal regulation of CaMKII activity in a similar fashion as CaMKIV. The observations by Facundo et al., that increasing O-GlcNAc was sufficient to initiate NFAT translocation [30], which is activated by the Ca<sup>2+</sup> sensitive phosphatase calcineurin, raises the possibility of other proteins involved in Ca<sup>2+</sup> signaling also being regulated by O-GlcNAcylation. In addition, it has recently been shown that OGT overexpression inhibited NFAT activation via increased O-GlcNAcylation of GSK3 $\beta$  [103]. Moreover, STIM1, a protein that regulates store-operated calcium signaling in neonatal cardiomyocytes is O-GlcNAcyated, which was shown to reduce its function [104]. Other Ca<sup>2+</sup> handling proteins have been reported to be O-GlcNAcyated including the inositol triphosphate receptor (IP<sub>3</sub>R) [105], PLB [52], and SERCA [58]. A recent study also showed that although SERCA was unaffected that phosphorylation of PLB and troponin I were reduced in OGT KO mice [106].

#### 1.5. Down regulation of O-GlcNAc levels

While there is considerable attention to mechanisms underlying either acute or chronic increases in O-GlcNAc levels, factors that might reduce O-GlcNAc levels are less well known (Fig. 1). Ngoh et al., reported that treatment of cardiomyocytes with H<sub>2</sub>O<sub>2</sub> decreased overall O-GlcNAcylation and this could be attenuated by inhibiting OGA with PUGNAc [107]. In the setting of hemorrhagic shock or I/R, low O-GlcNAc levels at the end of resuscitation or reperfusion correlated with increased indices of tissue injury in the heart and other tissues [108,109]. In both cases inhibition of OGA at the time of resuscitation/reperfusion attenuated the loss of O-GlcNAc as well as reduced the level of tissue injury. The specific mechanism underlying the loss of O-GlcNAc levels is unclear; however, Laczy et al., showed that both nuclear and cytosolic levels of OGT were significantly decreased following I/R and this was accompanied by high molecular weight OGT immunoreactive bands, possibly reflecting the accumulation of inactive


aggregates of OGT [24]. It is possible, therefore, that OGT is susceptible to damage induced by oxidative stress leading to decreased O-GlcNAc levels, and increased susceptibility to cellular injury. Inhibition of OGA appears to be protective in these circumstances, preventing the loss of O-GlcNAc levels and improving cell survival, however, the mechanisms by which this occurs are not well understood.

The above decreases in O-GlcNAc levels were all associated with pathophysiological conditions. Several studies have also suggested that exercise may result in decreased O-GlcNAc levels in the heart. Interestingly, in the mouse heart a single short bout of exercise lead to decrease in cytosolic O-GlcNAc and an increase in O-GlcNAc levels of lower molecular weight proteins in the nucleus [18]. There were no differences in OGT protein expression between sedentary and exercise groups, but O-GlcNAcylation of OGT was modestly reduced in response to exercise [18]. There was no evaluation of the effects of exercise on GFAT or OGA levels; however, the differential responses of cytosolic and nuclear O-GlcNAc levels highlight the importance of looking at subcellular distribution of O-GlcNAcylation in response to specific stimuli. Endurance training also resulted in a marked overall decrease in O-GlcNAc levels in the heart, which was associated with lower OGT protein levels and reduced mRNA levels of OGT, OGA, and GFAT2 [26]. The authors concluded that reduced O-GlcNAcylation may contribute to physiological hypertrophy [26].

Recently, we have shown that treatment of adult and neonatal cardiomyocytes with exogenous  $\text{NAD}^+$  resulted in a time- and dose-dependent decrease in cellular O-GlcNAc levels, which occurred in the absence of changes in OGT or OGA protein levels [77]; however, GFAT was not examined. In a later study, we showed that glucose deprivation induced increases in cardiac O-GlcNAc levels and that  $\text{NAD}^+$  treatment prevented this response to glucose deprivation [110]. Lee et al. have also shown that  $\text{NAD}^+$  treatment reduces O-GlcNAc levels, specifically on Sp1, which resulted in its degradation [111]. Interestingly,  $\text{NAD}^+$  and its precursors have been shown to be cardioprotective in the setting of I/R injury [112,113], which would seem counterintuitive given that lower O-GlcNAc levels have been associated with greater injury in similar settings [24]. However, the reduction in O-GlcNAc induced by  $\text{NAD}^+$  is modest and likely within normal homeostatic levels and thus unlikely to have adverse effects.  $\text{NAD}^+$  is increasingly recognized as playing an important role in cell signaling, well beyond its classical role as a redox carrier. Consequently, the influence of  $\text{NAD}^+$  on O-GlcNAc levels requires further studies to better understand the crosstalk between these two signaling pathways.

## 2. Conclusions

The regulation of O-GlcNAc in the heart, as well as other systems, has primarily focused on the role of increased nutrient availability, such as in the setting of hyperglycemia and diabetes, with an emphasis on the adverse effects of chronically elevated O-GlcNAc levels. There are however several studies that have shown that physiological and pathological stimuli can increase O-GlcNAc levels via transcriptional mechanisms as well as post-translational modifications. In addition, there is accumulating evidence of significant crosstalk between O-GlcNAc and  $\text{Ca}^{2+}$  signaling. There are a growing number of physiological agonists such as insulin, leptin, glucagon, ghrelin [114], and vasopressin [115] that have been shown to increase O-GlcNAc levels in range of different biological systems, highlighting the need to better understand how such agonists regulate cardiac O-GlcNAc levels. Consequently, it is increasingly apparent that cardiac O-GlcNAcylation is subject to dynamic regulation by a diverse range of physiological stimuli in addition to nutrient availability and that changes in O-GlcNAc levels can occur over varying time periods (Fig. 2). Different stresses can increase or decrease O-GlcNAc levels to levels beyond the optimal zone, potentially leading to cardiomyocyte dysfunction, depending of the duration of this response. Furthermore, an additional layer of complexity exists due to the known associations (or putative




**Fig. 2.** Regulation of protein O-GlcNAc homeostasis: Black line indicates changes in protein O-GlcNAc levels over an arbitrary period of time. In healthy cardiomyocytes, overall cellular O-GlcNAc levels vary within an optimal range over time periods of minutes, hours, or longer in response to different physiological stimuli due to changes in nutrient availability, regulation of GFAT, OGT, and OGA activities or alterations in the levels of these proteins. External stressors can lead to changes in O-GlcNAc levels beyond the optimal zone, either too high or too low, which can result in cellular dysfunction and potentially cell death depending on the duration of these excursions; however, brief pharmacologically induced increases in O-GlcNAc levels may be cardioprotective in the setting of ischemia/reperfusion or oxidative stress. This schematic illustrates overall changes in cellular O-GlcNAc levels and does not reflect the fact that O-GlcNAc levels can exhibit differential changes on individual proteins in response to both physiological and pathological stimuli; it also does not include the time of day dependent changes in O-GlcNAc that also occur in the heart.

associations) and cross talk between the regulation of OGT, OGA, GFAT, and O-GlcNAcylation and interactions with metabolic kinases and calcium signaling proteins (Fig. 3). Future studies focusing on shorter time-dependent changes in cardiac O-GlcNAc levels and smaller transient changes, are also important to help better integrate O-GlcNAcylation as a key component of the cardiomyocyte signaling network.

## Abbreviations

|                               |  |
|-------------------------------|--|
| AMPK                          | AMP-activated protein kinase   |
| CAMKII                        | Calcium/calmodulin-dependent protein kinase II                       |
| CAMKIV                        | Calcium/calmodulin-dependent protein kinase type IV                  |
| CREB                          | cAMP response element binding protein                                |
| eNOS                          | Endothelial nitric oxide synthase                                    |
| ET-1                          | Endothelin 1   |
| E2f1                          | E2F Transcription Factor 1   |
| FoxO                          | Forkhead transcription factors                                       |
| GD                            | glucose deprivation  |
| GFAT                          | Glutamine-fructose-6-phosphate aminotransferase                      |
| GSK3 $\beta$                  | Glycogen synthase kinase 3 $\beta$                                   |
| HBP                           | Hexosamine biosynthesis pathway                                      |
| H <sub>2</sub> O <sub>2</sub> | Hydrogen peroxide  |
| IRS1/2                        | Insulin receptor 1/2   |
| I/R                           | ischemia/reperfusion   |
| mTOR                          | mechanistic target of rapamycin                                      |
| NAD <sup>+</sup>              | Nicotinamide adenine dinucleotide                                    |
| NFAT                          | nuclear factor of activated T-cells                                  |
| O-GlcNAc                      | O-linked N-acetyl glucosamine  |
| OGT                           | O-GlcNAc transferase   |
| OGA                           | O-GlcNAcase  |
| PGC-1 $\alpha$                | Peroxisome proliferator-activated receptor gamma coactivator 1-alpha |



**Fig. 3.** Illustration of the complex interactions associated with the regulation by and of protein O-GlcNAcylation: Solid lines indicate established interactions, although not necessarily fully confirmed in the heart. Dotted lines indicate possible interactions that have yet to be established. There are no assumptions as to whether the interactions shown are positive or negative as this will likely be dependent on the specific stimulus and conditions (i.e., physiological or pathological). This is not a comprehensive illustration of all known interactions, but rather is focused on interactions discussed in the text with an emphasis on regulatory crosstalk known to be associated with O-GlcNAcylation or its regulatory enzymes (i.e. OGT, OGA, and GFAT). For example, both AMPK and CaMKII are known to regulate both OGT and GFAT and both are regulated by OGT; moreover, AMPK directly regulates glucose and fatty acid metabolism, which in turn influences HBP flux. In addition, AMPK contributes to transcriptional regulation of metabolism via its action on FoxO and PGC-1 $\alpha$ , which in turn are both targets for O-GlcNAcylation. All relevant citations and abbreviations are included in the main body of the manuscript. OGT/OGA represents the O-GlcNAc cycle and the interactions shown could be influenced by either one or both of proteins. Note: Blue = metabolites/metabolic pathways; Purple = transcription factors; Green = all other proteins.

|            |  |
|------------|--|
| PE         | Phenylephrine  |
| PDPK1      | Phosphoinositide dependent protein kinase 1                |
| PTM        | Post-translational modification                            |
| PKA        | Protein Kinase A   |
| SERCA      | Sarcoplasmic/endoplasmic reticulum Ca <sup>2+</sup> ATPase |
| Sp1        | Specificity factor 1                                       |
| TET        | Ten-eleven translocation                                   |
| UDP-GlcNAc | Uridine diphosphate-GlcNAc                                 |
| Xbp1s      | X-box binding protein 1s                                   |

## Funding

This work has been supported by a National Heart, Lung, and Blood Institute Grant (HL110366; JCC HL133011, HL142216), a UAB AMC21 reload multi-investigator grant to JCC and an American Diabetes Association Postdoctoral Fellowship (1-16-PDF-024; HEC).

## Transparency document

The Transparency document associated with this article can be found, in online version.

## Declaration of competing interest

The authors do not have any conflicts of interest and/or disclosures to declare.

## Acknowledgments

We would like to thank all members of the Chatham laboratory and members of the UAB O-GlcNAc interest group for valued discussions. Many thanks to Dr. Adam Wende for his comments on Fig. 3.

## References

- [1] C.R. Torres, G.W. Hart, Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc, *J. Biol. Chem.* 259 (1984) 3308–3317.
- [2] Z. Wang, M. Gucek, G.W. Hart, Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc, *Proc. Natl. Acad. Sci. U. S. A.* 105 (2008) 13793–13798.

- [3] S.A. Marsh, H.E. Collins, J.C. Chatham, Protein O-GlcNAcylation and cardiovascular (Patho)physiology, *J. Biol. Chem.* 289 (2014) 34449–34456.
- [4] J.N. Wright, H.E. Collins, A.R. Wende, J.C. Chatham, O-GlcNAcylation and cardiovascular disease, *Biochem. Soc. Trans.* 45 (2017) 545–553.
- [5] N.E. Zachara, G.W. Hart, O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress, *Biochim. Biophys. Acta* 1673 (2004) 13–28.
- [6] G.W. Hart, C. Slawson, G. Ramirez-Correa, O. Lagerlof, Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease, *Annu. Rev. Biochem.* 80 (2011) 825–858.
- [7] S. Marshall, V. Bacote, R.R. Traxinger, Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance, *J. Biol. Chem.* 266 (1991) 4706–4712.
- [8] A.A. Gibb, P.K. Lorkiewicz, Y.T. Zheng, X. Zhang, A. Bhatnagar, S.P. Jones, B.G. Hill, Integration of flux measurements to resolve changes in anabolic and catabolic metabolism in cardiac myocytes, *Biochem. J.* 474 (2017) 2785–2801.
- [9] A.K. Olson, B. Bouchard, W.Z. Zhu, J.C. Chatham, C. Des Rosiers, First characterization of glucose flux through the hexosamine biosynthesis pathway (HBP) in ex vivo mouse heart, *J. Biol. Chem.* (2020), <https://doi.org/10.1074/jbc.RA119.010565>.
- [10] E.P. Roquemore, M.R. Chevrier, R.J. Cotter, G.W. Hart, Dynamic O-GlcNAcylation of the small heat shock protein alpha B-crystallin, *Biochemistry* 35 (1996) 3578–3586.
- [11] H. Yki-Jarvinen, C. Vogt, P. Iozzo, R. Pipek, M.C. Daniels, A. Virkamaki, S. Makimattila, L. Mandarino, R.A. DeFronzo, D. McClain, W.K. Gottschalk, UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues, *Diabetologia* 40 (1997) 76–81.
- [12] X.L. Du, D. Edelstein, L. Rossetti, I.G. Fantus, H. Goldberg, F. Ziyadeh, J. Wu, M. Brownlee, Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation, *Proc. Natl. Acad. Sci. U. S. A.* 97 (2000) 12222–12226.
- [13] X.L. Du, D. Edelstein, S. Dimmeler, Q. Ju, C. Sui, M. Brownlee, Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site, *J. Clin. Invest.* 108 (2001) 1341–1348.
- [14] E.S. Fricovsky, J. Suarez, S.H. Ihm, B.T. Scott, J.A. Suarez-Ramirez, I. Banerjee, M. Torres-Gonzalez, H. Wang, I. Ellrott, L. Maya-Ramos, F. Villarreal, W.H. Dillmann, Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 303 (2012) R689–R699.
- [15] R.J. Clark, P.M. McDonough, E. Swanson, S.U. Trost, M. Suzuki, M. Fukuda, W.H. Dillmann, Diabetes and the accompanying hyperglycemia impairs cardiomyocyte cycling through increased nuclear O-GlcNAcylation, *J. Biol. Chem.* 278 (2003) 44230–44237.
- [16] N. Fulop, M.M. Mason, K. Dutta, P. Wang, A.J. Davidoff, R.B. Marchase, J.C. Chatham, The impact of type-2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart, *Am. J. Physiol. Cell Physiol.*

- 292 (2007) C1370–C1378.
- [17] J.R. Erickson, L. Pereira, L. Wang, G. Han, A. Ferguson, K. Dao, R.J. Copeland, F. Despa, G.W. Hart, C.M. Ripplinger, D.M. Bers, Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation, *Nature* 502 (2013) 372–376.
  - [18] E.J. Cox, S.A. Marsh, Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart, *Cardiovasc. Diabetol.* 12 (2013) 101.
  - [19] C.E. Bennett, V.L. Johnsen, J. Shearer, D.D. Belke, Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice, *Life Sci.* 92 (2013) 657–663.
  - [20] S.A. Marsh, L.J. Dell'Italia, J.C. Chatham, Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice, *Amino Acids* 40 (2011) 819–828.
  - [21] S.A. Marsh, P.C. Powell, L.J. Dell'Italia, J.C. Chatham, Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart, *Life Sci.* 92 (2013) 648–656.
  - [22] V. Champattanachai, R.B. Marchase, J.C. Chatham, Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc, *Am. J. Physiol. Cell Physiol.* 292 (2007) C178–C187.
  - [23] M. Ferron, J. Cadiet, A. Persello, V. Prat, M. Denis, A. Erraud, V. Aillerie, M. Mevel, E. Bigot, J.C. Chatham, C. Gauthier, B. Rozec, B. Lauzier, O-GlcNAc stimulation: a new metabolic approach to treat septic shock, *Sci. Rep.* 9 (2019) 18751.
  - [24] B. Lacz, S.A. Marsh, C.A. Brocks, I. Wittmann, J.C. Chatham, Inhibition of O-GlcNAc in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-GlcNAc-dependent manner, *Am. J. Physiol. Heart Circ. Physiol.* 299 (2010) H1715–H1727.
  - [25] L. Zou, S. Yang, P. Bounelis, J.C. Chatham, I.H. Chaudry, R.B. Marchase, Glucosamine improves recovery following trauma hemorrhage in rat, *FASEB J.* 19 (2005) A1224.
  - [26] D.D. Belke, Swim-exercised mice show a decreased level of protein O-GlcNAcylation and expression of O-GlcNAc transferase in heart, *J. Appl. Physiol.* 111 (2011) 157–162.
  - [27] X. Yang, K. Qian, Protein O-GlcNAcylation: emerging mechanisms and functions, *Nat. Rev. Mol. Cell Biol.* 18 (2017) 452–465.
  - [28] R.P. Taylor, T.S. Geisler, J.H. Chambers, D.A. McClain, Up-regulation of O-GlcNAc transferase with glucose deprivation in HepG2 cells is mediated by decreased hexosamine pathway flux, *J. Biol. Chem.* 284 (2009) 3425–3432.
  - [29] L. Zou, X. Zhu-Mauldin, R.B. Marchase, A.J. Paterson, J. Liu, Q. Yang, J.C. Chatham, Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent, *J. Biol. Chem.* 287 (2012) 34419–34431.
  - [30] H.T. Facundo, R.E. Brainard, L.J. Watson, G.A. Ngoh, T. Hamid, S.D. Prabhu, S.P. Jones, O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy, *Am. J. Physiol. Heart Circ. Physiol.* 302 (2012) H2122–H2130.
  - [31] I.G. Lunde, J.M. Aronsen, H. Kvaloy, E. Qvigstad, I. Sjaastad, T. Tonnessen, G. Christensen, L.M. Gronning-Wang, C.R. Carlson, Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure, *Physiol. Genomics* 44 (2012) 162–172.
  - [32] F. Mailleux, R. Gelinas, C. Beauloye, S. Horman, L. Bertrand, O-GlcNAcylation, enemy or ally during cardiac hypertrophy development? *Biochim. Biophys. Acta* 1862 (2016) 2232–2243.
  - [33] D. Ledee, L. Smith, M. Bruce, M. Kajimoto, N. Isern, M.A. Portman, A.K. Olson, c-Myc alters substrate utilization and O-GlcNAc protein posttranslational modifications without altering cardiac function during early aortic constriction, *PLoS One* 10 (2015) e0135262.
  - [34] M.V. Cannon, H.H. Sillje, J.W. Sijbesma, I. Vreeswijk-Baudoin, J. Ciapaite, B. van der Sluis, J. van Deursen, G.J. Silva, L.J. de Windt, J.A. Gustafsson, P. van der Harst, W.H. van Gilst, R.A. de Boer, Cardiac LXRalpha protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization, *EMBO Mol Med* 7 (2015) 1229–1243.
  - [35] J.C. Chatham, R.B. Marchase, The role of protein O-linked beta-N-acetylglucosamine in mediating cardiac stress responses, *Biochim. Biophys. Acta* 1800 (2010) 57–66.
  - [36] N. Fulop, W. Feng, D. Xing, K. He, L.G. Not, C.A. Brocks, R.B. Marchase, A.P. Miller, J.C. Chatham, Aging leads to increased levels of protein O-linked N-acetylglucosamine in heart, aorta, brain and skeletal muscle in Brown-Norway rats, *Biogerontology* 9 (2008) 139–151.
  - [37] P.S. Banerjee, O. Lagerlof, G.W. Hart, Roles of O-GlcNAc in chronic diseases of aging, *Mol. Asp. Med. Sci.* 1 (2016) 1–15.
  - [38] L. Zhao, Z. Feng, X. Zou, K. Cao, J. Xu, J. Liu, Aging leads to elevation of O-GlcNAcylation and disruption of mitochondrial homeostasis in retina, *Oxidative Med. Cell. Longev.* 2014 (2014) 425705.
  - [39] R. Gelinas, F. Mailleux, J. Dontaine, L. Bultot, B. Demeulder, A. Ginion, E.P. Daskalopoulos, H. Esfahani, E. Dubois-Deruy, B. Lauzier, C. Gauthier, A.K. Olson, B. Bouchard, C. Des Rosiers, B. Viollet, K. Sakamoto, J.L. Balligand, J.L. Vanoverschelde, C. Beauloye, S. Horman, L. Bertrand, AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation, *Nat. Commun.* 9 (2018) 374.
  - [40] V.V. Lima, F.R. Giachini, F.S. Carneiro, M.H. Carvalho, Z.B. Fortes, R.C. Webb, R.C. Tostes, O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/rho-kinase pathway, *Cardiovasc. Res.* 89 (2011) 614–622.
  - [41] V.V. Lima, F.R. Giachini, F.S. Carneiro, Z.N. Carneiro, M.A. Saleh, D.M. Pollock, Z.B. Fortes, M.H. Carvalho, A. Ergul, R.C. Webb, R.C. Tostes, O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1, *Hypertension* 55 (2010) 180–188.
  - [42] A.R. Wende, Post-translational modifications of the cardiac proteome in diabetes and heart failure, *Proteomics Clin. Appl.* 10 (2016) 25–38.
  - [43] S. Dassanayaka, S.P. Jones, O-GlcNAc and the cardiovascular system, *Pharmacol. Ther.* 142 (2014) 62–71.
  - [44] L.F. Hebert, M.C. Daniels, J. Zhou, E.D. Crook, R.L. Turner, S.T. Simmons, J.L. Neidigh, J.S. Zhu, A.D. Baron, D.A. McClain, Overexpression of glutamine-fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance, *J. Clin. Invest.* 98 (1996) 930–936.
  - [45] K. Vosseller, L. Wells, M.D. Lane, G.W. Hart, Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes, *Proc. Natl. Acad. Sci. U. S. A.* 99 (2002) 5313–5318.
  - [46] M.S. Macauley, X. Shan, S.A. Yuzwa, T.M. Gloster, D.J. Vocadlo, Elevation of global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis, *Chem. Biol.* 17 (2010) 949–958.
  - [47] M.S. Macauley, A.K. Bubbs, C. Martinez-Fleites, G.J. Davies, D.J. Vocadlo, Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance, *J. Biol. Chem.* 283 (2008) 34687–34695.
  - [48] M.E. Patti, A. Virkamaki, E.J. Landaker, C.R. Kahn, H. Yki-Jarvinen, Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle, *Diabetes* 48 (1999) 1562–1571.
  - [49] R.J. Copeland, J.W. Bullen, G.W. Hart, Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity, *Am. J. Physiol. Endocrinol. Metab.* 295 (2008) E17–E28.
  - [50] T. Issad, E. Masson, P. Pagesy, O-GlcNAc modification, insulin signaling and diabetic complications, *Diabetes Metab.* 36 (2010) 423–435.
  - [51] Y. Zhao, Z. Tang, T. Tao, C. Wan, X. Zhu, J. Huang, W. Zhang, N. Xia, S. Wang, S. Cui, D. Zhang, The role of PTP1B O-GlcNAcylation in hepatic insulin resistance, *Int. J. Mol. Sci.* 16 (2015) 22856–22869.
  - [52] S. Yokoe, M. Asahi, T. Takeda, K. Otsu, N. Taniguchi, E. Miyoshi, K. Suzuki, Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy, *Glycobiology* 20 (2010) 1217–1226.
  - [53] Y. Hu, D. Belke, J. Suarez, E. Swanson, R. Clark, M. Hoshijima, W.H. Dillmann, Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart, *Circ. Res.* 96 (2005) 1006–1013.
  - [54] G.A. Ramirez-Correa, W. Jin, Z. Wang, X. Zhong, W.D. Gao, W.B. Dias, C. Vecoli, G.W. Hart, A.M. Murphy, O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function, *Circ. Res.* 103 (2008) 1354–1358.
  - [55] G.A. Ramirez-Correa, J. Ma, C. Slawson, Q. Zeidan, N.S. Lugo-Fagundo, M. Xu, X. Shen, W.D. Gao, V. Caceres, K. Chakir, L. DeVine, R.N. Cole, L. Marchionni, N. Paolucci, G.W. Hart, A.M. Murphy, Removal of abnormal myofilament O-GlcNAcylation restores Ca<sup>2+</sup> sensitivity in diabetic cardiac muscle, *Diabetes* 64 (2015) 3573–3587.
  - [56] P.S. Banerjee, J. Ma, G.W. Hart, Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria, *Proc. Natl. Acad. Sci. U. S. A.* 112 (2015) 6050–6055.
  - [57] Y. Hu, J. Suarez, E. Fricovsky, H. Wang, B.T. Scott, S.A. Trauger, W. Han, M.O. Oyeleye, W.H. Dillmann, Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose, *J. Biol. Chem.* 284 (2009) 547–555.
  - [58] V.L. Johnsen, D.D. Belke, C.C. Hughey, D.S. Hittel, R.T. Hepple, L.G. Koch, S.L. Britton, J. Shearer, Enhanced cardiac protein glycosylation (O-GlcNAc) of selected mitochondrial proteins in rats artificially selected for low running capacity, *Physiol. Genomics* 45 (2013) 17–25.
  - [59] B. Lacz, N. Fulop, A. Onay-Besikci, C. Des Rosiers, J.C. Chatham, Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation, *PLoS One* 6 (2011) e18417.
  - [60] B. Lauzier, F. Vaillant, C. Merlen, R. Gelinas, B. Bouchard, M.E. Rivard, F. Labarthe, V.W. Dolinsky, J.R. Dyck, B.G. Allen, J.C. Chatham, C. Des Rosiers, Metabolic effects of glutamine on the heart: anaplerosis versus the hexosamine biosynthetic pathway, *J. Mol. Cell. Cardiol.* 55 (2013) 92–100.
  - [61] B. Luo, G.J. Parker, R.C. Cooksey, Y. Soesanto, M. Evans, D. Jones, D.A. McClain, Chronic hexosamine flux stimulates fatty acid oxidation by activating AMP-activated protein kinase in adipocytes, *J. Biol. Chem.* 282 (2007) 7172–7180.
  - [62] C.N. Keembiyehetty, A. Krzeslak, D.C. Love, J.A. Hanover, A lipid-droplet-targeted O-GlcNAcase isoform is a key regulator of the proteasome, *J. Cell Sci.* 124 (2011) 2851–2860.
  - [63] Z.A. Bacigalupa, C.H. Bhadiadra, M.J. Reginato, O-GlcNAcylation: key regulator of glycolytic pathways, *J. Bioenerg. Biomembr.* 50 (2018) 189–198.
  - [64] H. Taegtmeier, A. Karlstaedt, M.L. Rees, G. Davogusto, Oncometabolic tracks in the heart, *Circ. Res.* 120 (2017) 267–269.
  - [65] A. Karlstaedt, W. Schiffer, H. Taegtmeier, Actionable metabolic pathways in heart failure and cancer-lessons from cancer cell metabolism, *Front Cardiovasc Med* 5 (2018) 71.
  - [66] M.P. Housley, J.T. Rodgers, N.D. Udeshi, T.J. Kelly, J. Shabanowitz, D.F. Hunt, P. Puigserver, G.W. Hart, O-GlcNAc regulates FoxO activation in response to glucose, *J. Biol. Chem.* 283 (2008) 16283–16292.
  - [67] M.P. Housley, N.D. Udeshi, J.T. Rodgers, J. Shabanowitz, P. Puigserver, D.F. Hunt, G.W. Hart, A PGC-1alpha-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose, *J. Biol. Chem.* 284 (2009) 5148–5157.
  - [68] J.E. Rexach, P.M. Clark, D.E. Mason, R.L. Neve, E.C. Peters, L.C. Hsieh-Wilson, Dynamic O-GlcNAc modification regulates CREB-mediated gene expression and

- memory formation, *Nat. Chem. Biol.* 8 (2012) 253–261.
- [69] N. Jin, D. Ma, J. Gu, X. Shi, X. Xu, K. Iqbal, C.X. Gong, F. Liu, D. Chu, O-GlcNAcylation modulates PKA-CREB signaling in a manner specific to PKA catalytic subunit isoforms, *Biochem. Biophys. Res. Commun.* 497 (2018) 194–199.
- [70] J.W. Bullen, J.L. Balsbaugh, D. Chanda, J. Shabanowitz, D.F. Hunt, D. Neumann, G.W. Hart, Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK), *J. Biol. Chem.* 289 (2014) 10592–10606.
- [71] S. Eguchi, N. Oshiro, T. Miyamoto, K. Yoshino, S. Okamoto, T. Ono, U. Kikkawa, K. Yonezawa, AMP-activated protein kinase phosphorylates glutamine: fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity, *Genes Cells* 14 (2009) 179–189.
- [72] Y. Li, C. Roux, S. Lazereg, J.P. LeCaer, O. Laprevote, B. Badet, M.A. Badet-Denisot, Identification of a novel serine phosphorylation site in human glutamine:fructose-6-phosphate amidotransferase isoform 1, *Biochemistry* 46 (2007) 13163–13169.
- [73] N.E. Zachara, N. O'Donnell, W.D. Cheung, J.J. Mercer, J.D. Marth, G.W. Hart, Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells, *J. Biol. Chem.* 279 (2004) 30133–30142.
- [74] S.P. Jones, N.E. Zachara, G.A. Ngoh, B.G. Hill, Y. Teshima, A. Bhatnagar, G.W. Hart, E. Marban, Cardioprotection by N-acetylglucosamine linkage to cellular proteins, *Circulation* 117 (2008) 1172–1182.
- [75] Z.V. Wang, Y. Deng, N. Gao, Z. Pedrozo, D.L. Li, C.R. Morales, A. Criollo, X. Luo, W. Tan, N. Jiang, M.A. Lehrman, B.A. Rothermel, A.H. Lee, S. Lavandero, P.P. Mammen, A. Ferdous, T.G. Gillette, P.E. Scherer, J.A. Hill, Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway, *Cell* 156 (2014) 1179–1192.
- [76] C. Chaveroux, C. Sarcinelli, V. Barbet, S. Belfeki, A. Barthelaix, C. Ferraro-Peyret, S. Lebecque, T. Renno, A. Bruhat, P. Fafouroux, S.N. Manie, Nutrient shortage triggers the hexosamine biosynthetic pathway via the GCN2-ATF4 signalling pathway, *Sci. Rep.* 6 (2016) 27278.
- [77] D.J. Durgan, B.M. Pat, B. Lacy, J.A. Bradley, J.Y. Tsai, M.H. Grenett, W.F. Ratcliffe, R.A. Brewer, J. Nagendran, C. Villegas-Montoya, C. Zou, L. Zou, R.L. Johnson Jr., J.R. Dyck, M.S. Bray, K.L. Gamble, J.C. Chatham, M.E. Young, O-GlcNAcylation, novel post-translational modification linking myocardial metabolism and cardiomyocyte circadian clock, *J. Biol. Chem.* 286 (2011) 44606–44619.
- [78] A. Berthier, M. Vinod, G. Porez, A. Steenackers, J. Alexandre, N. Yamakawa, C. Gheeraert, M. Ploton, X. Marechal, J. Dubois-Chevalier, A. Hovasse, C. Schaeffer-Reiss, S. Cianferani, C. Rolando, F. Bray, H. Duez, J. Eeckhoutte, T. Lefebvre, B. Staels, P. Lefebvre, Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERBalpha complex, *Proc. Natl. Acad. Sci. U. S. A.* 115 (2018) E11033–E11042.
- [79] Z. Zhang, E.P. Tan, N.J. VandenHull, K.R. Peterson, C. Slawson, O-GlcNAcase expression is sensitive to changes in O-GlcNAc homeostasis, *Front. Endocrinol. (Lausanne)* 5 (2014) 206.
- [80] S.K. Park, X. Zhou, K.E. Pendleton, O.V. Hunter, J.J. Kohler, K.A. O'Donnell, N.K. Conrad, A conserved splicing silencer dynamically regulates O-GlcNAc transferase intron retention and O-GlcNAc homeostasis, *Cell Rep.* 20 (2017) 1088–1099.
- [81] K. Qian, S. Wang, M. Fu, J. Zhou, J.P. Singh, M.D. Li, Y. Yang, K. Zhang, J. Wu, Y. Nie, H.B. Ruan, X. Yang, Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer, *J. Biol. Chem.* 293 (2018) 13989–14000.
- [82] S. Muthusamy, K.U. Hong, S. Dassanayaka, T. Hamid, S.P. Jones, E2F1 transcription factor regulates O-linked N-acetylglucosamine (O-GlcNAc) transferase and O-GlcNAcase expression, *J. Biol. Chem.* 290 (2015) 31013–31024.
- [83] L. Wells, C. Slawson, G.W. Hart, The E2F-1 associated retinoblastoma-susceptibility gene product is modified by O-GlcNAc, *Amino Acids* 40 (2011) 877–883.
- [84] S. Dassanayaka, K.R. Brittan, A. Jurkovic, L.A. Higgins, T.N. Audam, B.W. Long, L.T. Harrison, G. Militello, D.W. Riggs, M.G. Chitre, S. Uchida, S. Muthusamy, A.M. Gumpert, S.P. Jones, E2F1 deletion attenuates infarct-induced ventricular remodeling without affecting O-GlcNAcylation, *Basic Res. Cardiol.* 114 (2019) 28.
- [85] C. Zhang, F. Xie, L. Li, C. Zhang, Y. Zhang, W. Ying, L. Liu, X. Yan, F. Yin, L. Zhang, Hepatocyte nuclear factor 1 alpha (HNF1A) regulates transcription of O-GlcNAc transferase in a negative feedback mechanism, *FEBS Lett.* 593 (2019) 1050–1060.
- [86] S. Muthusamy, A.M. DeMartino, L.J. Watson, K.R. Brittan, A. Zafir, S. Dassanayaka, K.U. Hong, S.P. Jones, MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression, *J. Biol. Chem.* 289 (2014) 29665–29676.
- [87] S. Milewski, Glucosamine-6-phosphate synthase - the multi-facets enzyme, *Biochim. Biophys. Acta* 1597 (2002) 173–192.
- [88] Y. Hu, L. Riesland, A.J. Paterson, J.E. Kudlow, Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase increases the enzyme activity, *J. Biol. Chem.* 279 (2004) 29988–29993.
- [89] Q. Chang, K. Su, J.R. Baker, X. Yang, A.J. Paterson, J.E. Kudlow, Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity, *J. Biol. Chem.* 275 (2000) 21981–21987.
- [90] J.G. Moloughney, N.M. Vega-Cotto, S. Liu, C. Patel, P.K. Kim, C.C. Wu, D. Albaciete, C. Magaway, A. Chang, S. Rajput, X. Su, G. Werlen, E. Jacinto, mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation, *J. Biol. Chem.* 293 (2018) 16464–16478.
- [91] P.V. Hornbeck, B. Zhang, B. Murray, J.M. Kornhauser, V. Latham, E. Skrzypek, PhosphoSitePlus, 2014: mutations, PTMs and recalibrations, *Nucleic Acids Res.* 43 (2015) D512–D520.
- [92] K. Kaasik, S. Kivimae, J.J. Allen, R.J. Chalkley, Y. Huang, K. Baer, H. Kissel, A.L. Burlingame, K.M. Shokat, L.J. Ptacek, Y.H. Fu, Glucose sensor O-GlcNAcylation coordinates with phosphorylation to regulate circadian clock, *Cell Metab.* 17 (2013) 291–302.
- [93] S.A. Whelan, M.D. Lane, G.W. Hart, Regulation of the O-linked beta-N-acetylglucosamine transferase by insulin signaling, *J. Biol. Chem.* 283 (2008) 21411–21417.
- [94] H.B. Ruan, Y. Ma, S. Torres, B. Zhang, C. Feriod, R.M. Heck, K. Qian, M. Fu, X. Li, M.H. Nathanson, A.M. Bennett, Y. Nie, B.E. Ehrlich, X. Yang, Calcium-dependent O-GlcNAc signaling drives liver autophagy in adaptation to starvation, *Genes Dev.* 31 (2017) 1655–1665.
- [95] X. Hu, Z. Li, Y. Ding, Q. Geng, Z. Xiahou, H. Ru, M.Q. Dong, X. Xu, J. Li, Chk1 modulates the interaction between myosin phosphatase targeting protein 1 (MYPT1) and protein phosphatase 1c beta (PP1c beta), *Cell Cycle* 17 (2018) 421–427.
- [96] L. Xie, X. Pi, Z. Wang, J. He, M.S. Willis, C. Patterson, Depletion of PHD3 protects heart from ischemia/reperfusion injury by inhibiting cardiomyocyte apoptosis, *J. Mol. Cell. Cardiol.* 80 (2015) 156–165.
- [97] M. Song, H.S. Kim, J.M. Park, S.H. Kim, I.H. Kim, S.H. Ryu, P.G. Suh, o-GlcNAc transferase is activated by CaMKIV-dependent phosphorylation under potassium chloride-induced depolarization in NG-108-15 cells, *Cell. Signal.* 20 (2008) 94–104.
- [98] Z.T. Kneass, R.B. Marchase, Neutrophils exhibit rapid agonist-induced increases in protein-associated O-GlcNAc, *J. Biol. Chem.* 279 (2004) 45759–45765.
- [99] A.D. Zimmerman, R.B. Harris, In vivo and in vitro evidence that chronic activation of the hexosamine biosynthetic pathway interferes with leptin-dependent STAT3 phosphorylation, *American journal of physiology, Am. J. Physiol. Regul. Integr. Comp. Physiol.* 308 (2015) R543–R555.
- [100] D.L. Hutton, P.A. Lucchesi, Y. Pang, X. Cheng, L.J. Dell'Italia, R.B. Marchase, Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes, *J. Biol. Chem.* 277 (2002) 14266–14273.
- [101] Y. Pang, D.L. Hutton, P. Bounelis, R.B. Marchase, Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes, *Diabetes* 51 (2002) 3461–3467.
- [102] W.B. Dias, W.D. Cheung, Z. Wang, G.W. Hart, Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification, *J. Biol. Chem.* 284 (2009) 21327–21337.
- [103] T. Nakagawa, Y. Furukawa, T. Hayashi, A. Nomura, S. Yokoe, K. Moriwaki, R. Kato, Y. Ijiri, T. Yamaguchi, Y. Izumi, M. Yoshiyama, M. Asahi, Augmented O-GlcNAcylation attenuates intermittent hypoxia-induced cardiac remodeling through the suppression of NFAT and NF-kappaB activities in mice, *Hypertens. Res.* 42 (2019) 1858–1871.
- [104] X. Zhu-Mauldin, S.A. Marsh, L. Zou, R.B. Marchase, J.C. Chatham, Modification of STIM1 by O-linked N-acetylglucosamine (O-GlcNAc) attenuates store-operated calcium entry in neonatal cardiomyocytes, *J. Biol. Chem.* 287 (2012) 39094–39106.
- [105] J. Rengifo, C.J. Gibson, E. Winkler, T. Collin, B.E. Ehrlich, Regulation of the inositol 1,4,5-trisphosphate receptor type I by O-GlcNAc glycosylation, *J. Neurosci.* 27 (2007) 13813–13821.
- [106] W.Z. Zhu, D. El-Nachef, X. Yang, D. Ledee, A.K. Olson, O-GlcNAc transferase promotes compensated cardiac function and protein kinase A O-GlcNAcylation during early and established pathological hypertrophy from pressure overload, *J. Am. Heart Assoc.* 8 (2019) e011260.
- [107] G.A. Ngoh, L.J. Watson, H.T. Facundo, S.P. Jones, Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes, *Amino Acids* 40 (2011) 895–911.
- [108] L.G. Not, R.B. Marchase, N. Fulop, C.A. Brocks, J.C. Chatham, Glucosamine administration improves survival rate after severe hemorrhagic shock combined with trauma in rats, *Shock* 28 (2007) 345–352.
- [109] L.Y. Zou, S. Yang, I.H. Chaudry, R.B. Marchase, J.C. Chatham, PUGNAc administration during resuscitation improves organ function following trauma-hemorrhage, *Shock* 27 (2007) 402–408.
- [110] L. Zou, Marchase, R.B., Chatham, J.C., The effects of NAD on glucose deprivation induced activation of protein O-GlcNAcylation, ER stress and autophagy mediated by CD38 and cADPR, *Faseb journal*, 29.1 supplement.798.4 (2015).
- [111] H.I. Lee, H.J. Cho, J.A. Han, S.Y. Jang, K.M. Wang, H.T. Kang, E.S. Hwan, Transient downregulation of protein O-N-acetylglucosaminylase by treatment of high-dose nicotinamide in human cells, *Exp. Mol. Med.* 40 (2008) 246–253.
- [112] T. Yamamoto, J. Byun, P. Zhai, Y. Ikeda, S. Oka, J. Sadoshima, Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion, *PLoS One* 9 (2014) e98972.
- [113] S.M. Nadtochiy, Y.T. Wang, K. Nehrke, J. Munger, P.S. Brookes, Cardioprotection by nicotinamide mononucleotide (NMN): involvement of glycolysis and acidic pH, *J. Mol. Cell. Cardiol.* 121 (2018) 155–162.
- [114] H.B. Ruan, M.O. Dietrich, Z.W. Liu, M.R. Zimmer, M.D. Li, J.P. Singh, K. Zhang, R. Yin, J. Wu, T.L. Horvath, X. Yang, O-GlcNAc transferase enables AgRP neurons to suppress browning of white fat, *Cell* 159 (2014) 306–317.
- [115] J.D. Hoffert, T. Pisitkun, F. Saeed, J.H. Song, C.L. Chou, M.A. Knepper, Dynamics of the G protein-coupled vasopressin V2 receptor signaling network revealed by quantitative phosphoproteomics, *Molecular & Cellular Proteomics: MCP* 11 (M11) (2012) 14613.